

Edgar Filing: PER SE TECHNOLOGIES INC - Form 8-K

PER SE TECHNOLOGIES INC  
Form 8-K  
June 19, 2003

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 19, 2003

PER-SE TECHNOLOGIES, INC.  
(Exact Name of Registrant as Specified in its Charter)

Delaware (State or Other Jurisdiction of Incorporation)	000-19480 (Commission File No.)	58-1651222 (IRS Employer Identification No.)
---------------------------------------------------------------	------------------------------------	----------------------------------------------------

2840 Mt. Wilkinson Parkway, Atlanta, Georgia (Address of Principal Executive Offices)	30339 (Zip Code)
------------------------------------------------------------------------------------------	---------------------

(770) 444-5300  
(Registrant's Telephone Number, Including Area Code)

Item 5. Other Events and Regulation FD Disclosure.

On June 19, 2003, Per-Se Technologies, Inc. issued a press release announcing that it has agreed to sell its Patient 1(R)clinical product line to Misys Healthcare Systems, a division of Misys plc (London: MSY.L). A copy of the press release is furnished as Exhibit 99.1 to this current report.

Item 7. Financial Statements, Pro Forma Financial Financial Information and Exhibits.

(c) Exhibits

- 99.1 Press Release dated June 19, 2003, announcing agreement to sell Patient 1(R) product line.

Signatures  
-----

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the

Edgar Filing: PER SE TECHNOLOGIES INC - Form 8-K

undersigned thereunto duly authorized.

Date: June 19, 2003

PER-SE TECHNOLOGIES, INC.

By: /s/\_CHRIS\_E.\_PERKINS\_\_\_\_\_  
Chris E. Perkins  
Executive Vice President  
and Chief Financial Officer

EXHIBIT INDEX

Exhibit

No.  
---

Description  
-----

99.1 Press Release dated June 19, 2003, announcing agreement to sell Patient 1(R) product line.